• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.

作者信息

Montalban-Bravo Guillermo, Hammond Danielle, DiNardo Courtney D, Konopleva Marina, Borthakur Gautam, Short Nicholas J, Ramos-Perez Jorge, Guerra Veronica, Kanagal-Shamanna Rashmi, Naqvi Kiran, Sasaki Koji, Jabbour Elias, Pemmaraju Naveen, Kadia Tapan M, Ravandi Farhad, Daver Naval, Estrov Zeev, Pierce Sherry, Kantarjian Hagop, Garcia-Manero Guillermo

机构信息

Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leukemia. 2021 May;35(5):1494-1499. doi: 10.1038/s41375-021-01240-2. Epub 2021 Apr 12.

DOI:10.1038/s41375-021-01240-2
PMID:33846541
Abstract
摘要

相似文献

1
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.基于维奈托克的疗法在慢性粒单核细胞白血病中的活性。
Leukemia. 2021 May;35(5):1494-1499. doi: 10.1038/s41375-021-01240-2. Epub 2021 Apr 12.
2
Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia.基于维奈托克的疗法在慢性期和急变期慢性粒单核细胞白血病中的疗效
Am J Hematol. 2021 Nov 1;96(11):E433-E436. doi: 10.1002/ajh.26334. Epub 2021 Sep 12.
3
Double remission of simultaneously occurring secondary AML and CLL by venetoclax monotherapy.维奈托克单药治疗同时发生的继发性急性髓系白血病和慢性淋巴细胞白血病实现双重缓解
Acta Oncol. 2019 Jun;58(6):888-890. doi: 10.1080/0284186X.2019.1585943. Epub 2019 Mar 8.
4
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.先前接受过低甲基化剂治疗的继发性 AML 患者的一线治疗方法对其结局的影响。
J Hematol Oncol. 2022 Jan 29;15(1):12. doi: 10.1186/s13045-022-01229-z.
5
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.美国接受维奈托克治疗的慢性淋巴细胞白血病患者的真实世界结局和管理策略。
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
6
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.维奈托克和伊布替尼用于复发/难治性慢性淋巴细胞白血病患者。
Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.
7
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.接受维奈托克单药治疗的慢性淋巴细胞白血病患者凋亡机制中复发性基因组改变的鉴定
Am J Hematol. 2022 Feb 1;97(2):E47-E51. doi: 10.1002/ajh.26411. Epub 2021 Nov 24.
8
Decitabine plus cedazuridine and venetoclax: the promise of an all-oral therapy for patients with myelodysplastic syndromes and chronic myelomonocytic leukaemia.地西他滨联合西扎胞苷和维奈克拉：为骨髓增生异常综合征和慢性粒单核细胞白血病患者带来全口服疗法的希望。
Lancet Haematol. 2024 Mar;11(3):e170-e171. doi: 10.1016/S2352-3026(24)00001-2. Epub 2024 Feb 2.
9
Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.维奈托克用于接受一种以上B细胞受体途径抑制剂治疗后病情进展的慢性淋巴细胞白血病患者。
Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27.
10
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.在初治的TP53基因异常的慢性淋巴细胞白血病患者中持续使用维奈托克：一项慢性淋巴细胞白血病领域研究
Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.

引用本文的文献

1
Decoding the immune microenvironment of secondary chronic myelomonocytic leukemia due to diffuse large B-cell lymphoma with CD19 CAR-T failure by single-cell RNA-sequencing.通过单细胞RNA测序解析弥漫性大B细胞淋巴瘤伴CD19嵌合抗原受体T细胞（CAR-T）治疗失败所致继发性慢性粒单核细胞白血病的免疫微环境
Chin Med J (Engl). 2025 Aug 5;138(15):1866-1881. doi: 10.1097/CM9.0000000000003690. Epub 2025 Jul 7.
2
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study.去甲基化药物联合维奈克拉用于高危骨髓增生异常综合征和慢性粒-单核细胞白血病作为移植的桥接治疗：一项GESMD研究
Exp Hematol Oncol. 2025 Apr 26;14(1):61. doi: 10.1186/s40164-025-00652-5.
3
An integrative multiparametric approach stratifies putative distinct phenotypes of blast phase chronic myelomonocytic leukemia.
一种综合多参数方法对急变期慢性粒单核细胞白血病的假定不同表型进行分层。
Cell Rep Med. 2025 Feb 18;6(2):101933. doi: 10.1016/j.xcrm.2025.101933. Epub 2025 Jan 31.
4
Prognostic Significance and Treatment Response Associations of Genetic Mutations in Chronic Myelomonocytic Leukemia: A Retrospective Cohort Study.慢性粒单核细胞白血病基因突变的预后意义及治疗反应相关性：一项回顾性队列研究
Biomedicines. 2024 Oct 28;12(11):2476. doi: 10.3390/biomedicines12112476.
5
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.维奈托克联合低甲基化药物治疗慢性粒单核细胞白血病：一项倾向评分匹配的多中心队列研究。
Leukemia. 2025 Jan;39(1):257-260. doi: 10.1038/s41375-024-02466-6. Epub 2024 Nov 12.
6
Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges.老年骨髓增生异常综合征患者的异基因造血细胞移植：考量与挑战
Semin Hematol. 2024 Dec;61(6):420-430. doi: 10.1053/j.seminhematol.2024.10.004. Epub 2024 Oct 17.
7
Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations.慢性粒单核细胞白血病：分子发病机制与治疗创新
Haematologica. 2025 Jan 1;110(1):22-36. doi: 10.3324/haematol.2024.286061.
8
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.针对 MCL1 驱动的抗凋亡途径可克服低甲基化剂治疗失败后慢性粒单核细胞白血病中的原始细胞进展。
Cell Rep Med. 2024 Jun 18;5(6):101585. doi: 10.1016/j.xcrm.2024.101585. Epub 2024 May 22.
9
Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.慢性粒单核细胞白血病：2024 年诊断、风险分层和治疗更新。
Am J Hematol. 2024 Jun;99(6):1142-1165. doi: 10.1002/ajh.27271. Epub 2024 Mar 7.
10
Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.骨髓增生异常/骨髓增殖性肿瘤的定义、生物学特性及当前治疗概况
Cancers (Basel). 2023 Jul 27;15(15):3815. doi: 10.3390/cancers15153815.